For many patients battling cancer, the physical toll of chemotherapy and radiotherapy is compounded by a hidden, exhausting burden: the logistics of getting to the hospital. In Belgium, a growing number of patients are discovering that the safety net intended to cover these travel expenses is fraying, leaving them to shoulder significant costs during their most vulnerable moments.
The controversy centers on evolving interpretations and stricter applications of rules regarding cancer patient transport costs in Belgium, managed by the National Institute for Health and Disability Insurance (RIZIV/INAMI). Patients and advocacy groups report that administrative hurdles and rigid distance calculations are preventing people from accessing reimbursements they previously relied upon, leading some to describe the current administrative framework as “sick.”
As a physician, I have seen how “financial toxicity”—the distress caused by the cost of cancer care—can actively hinder recovery. When a patient must choose between the cost of a taxi to a radiotherapy session and their monthly grocery bill, the medical treatment is no longer the only battle they are fighting. The current friction within the Belgian reimbursement system is not merely a clerical issue; it is a barrier to healthcare accessibility.
The Administrative Friction in Patient Transport
Under the Belgian healthcare system, patients with specific chronic or severe conditions, including cancer, are eligible for the reimbursement of transport costs to and from medical consultations and treatments. What we have is particularly critical for radiotherapy, which often requires daily visits to a specialized center for several consecutive weeks.
However, recent reports indicate a shift in how these claims are processed. Patients are encountering stricter requirements for medical certificates and a rigid adherence to “standardized” distances. In many cases, the system calculates the shortest possible route or a fixed distance that does not account for the patient’s actual physical condition or the necessity of specific transport modes (such as taxis for those too ill to drive or use public transit).
The result is a gap between the actual expense incurred by the patient and the amount reimbursed by the National Institute for Health and Disability Insurance (RIZIV/INAMI). For patients requiring daily treatment, these small discrepancies accumulate into hundreds of euros over a single course of therapy.
The Human Toll of ‘Financial Toxicity’
The impact of these rules extends beyond the wallet. The psychological stress of fighting a bureaucratic system while undergoing aggressive treatment can lead to increased anxiety and depression, which are known to negatively affect clinical outcomes. When the system designed to support the patient becomes a source of stress, it undermines the holistic goal of oncology care.
Advocacy groups have highlighted that the current rules often fail to recognize the reality of a cancer patient’s life. A patient who has just undergone a grueling session of chemotherapy may be physically incapable of navigating a bus route, yet they may find their request for taxi reimbursement denied given that the “standard” distance or mode of transport was not met.
The frustration is echoed by those who argue that the system is prioritizing budgetary efficiency over human dignity. The sentiment that “the system is sick” reflects a feeling of betrayal—that in a country with one of the most comprehensive healthcare systems in the world, the basic act of reaching the clinic has become a financial gamble.
Comparing the Patient Experience vs. Regulatory Requirements
The tension often arises from the difference between the clinical necessity of the patient and the administrative checkboxes of the insurer.
| Patient Necessity | Regulatory Constraint | Resulting Impact |
|---|---|---|
| Door-to-door transport due to extreme fatigue | Strict “shortest route” or public transit default | Out-of-pocket costs for taxis |
| Daily trips for multi-week radiotherapy | Capped daily or monthly reimbursement limits | Financial exhaustion by complete of treatment |
| Urgent changes in appointment times | Rigid pre-approval requirements for transport | Delayed care or unpaid travel |
Systemic Barriers to Care
The issue is not isolated to a few individuals but appears to be a systemic failure in how transport eligibility is assessed. The criteria for “medical necessity” are often interpreted narrowly by administrators who are not clinicians. From a medical perspective, the “necessity” of transport is not just about the distance from point A to point B, but the patient’s functional status—their ability to walk, their immune system’s vulnerability to crowded public spaces and their cognitive state during treatment.
the burden of proof has shifted heavily onto the patient. Requiring a physician to repeatedly justify the need for specific transport for every single visit creates an additional administrative load on an already overburdened healthcare workforce. This creates a secondary bottleneck where patients may not gain the necessary paperwork in time to secure their reimbursement.
Experts in public health argue that for a healthcare system to be truly effective, it must address the “social determinants of health,” which include transportation. If a patient misses a radiotherapy session because they cannot afford the trip, the efficacy of the entire treatment plan is compromised, potentially leading to poorer survival rates or a higher likelihood of recurrence.
Looking Toward a Solution
Patient advocates are calling for a more flexible, patient-centered approach to transport reimbursements. This would include a “presumptive eligibility” for certain types of cancer treatments, where the need for specialized transport is recognized automatically based on the diagnosis and treatment plan, rather than requiring a case-by-case battle with administrators.
There is similarly a push for the Belgian Federal Public Service Health to modernize the reimbursement software to account for real-world travel conditions and the specific fragility of oncology patients.
Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. Patients seeking reimbursement for medical expenses should consult with their healthcare provider or a qualified legal professional regarding their specific case.
The next critical step will be the upcoming review of healthcare accessibility guidelines by the Belgian health ministry, where patient advocacy groups are expected to present formal grievances and proposed amendments to the transport reimbursement framework. Whether the government will prioritize administrative austerity or patient accessibility remains to be seen.
Do you or a loved one have experience navigating medical transport reimbursements? Share your story in the comments below or share this article to raise awareness about financial toxicity in cancer care.
